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Background: Initial appropriate anti-infective therapy is associated with improved outcomes in patients with
severe infections. In critically ill patients, altered pharmacokinetic (PK) behaviour is common and known to
influence the achievement of PK/pharmacodynamic targets.
Objectives: To describe population PK and optimized dosing regimens for flucloxacillin in critically ill patients.
Methods: First, we developed a population PK model, estimated between-patient variability (BPV) and identified
covariates that could explain BPV through non-linear mixed-effects analysis, using total and unbound concen-
trations obtained from 35 adult critically ill patients treated with intermittent flucloxacillin. Second, we validated
the model using external datasets from two different countries. Finally, frequently prescribed dosing regimens
were evaluated using Monte Carlo simulations.
Results: A two-compartment model with non-linear protein binding was developed and validated. BPV of the
maximum binding capacity decreased from 42.2% to 30.4% and BPV of unbound clearance decreased from
88.1% to 71.6% upon inclusion of serum albumin concentrations and estimated glomerular filtration rate (eGFR;
by CKD-EPI equation), respectively. PTA (target of 100%fT>MIC) was 91% for patients with eGFR of 33 mL/min and
1 g q6h, 87% for patients with eGFR of 96 mL/min and 2 g q4h and 71% for patients with eGFR of 153 mL/min
and 2 g q4h.
Conclusions: For patients with high creatinine clearance who are infected with moderately susceptible patho-
gens, therapeutic drug monitoring is advised since there is a risk of underexposure to flucloxacillin. Due to the
non-linear protein binding of flucloxacillin and the high prevalence of hypoalbuminaemia in critically ill patients,
dose adjustments should be based on unbound concentrations.
Introduction
Severe infection is recognized as an important determinant of out-
come for patients in the ICU.1 Initial appropriate anti-infective
therapy, implying both a timely commencement of treatment
with a spectrum appropriate for the targeted pathogen and ad-
equate exposure to this antimicrobial agent, is associated with
significantly improved clinical outcomes in patients with severe
infections.2–4 However, antibiotic selection and dosing is often
challenging in critically ill patients because of disease complexity,
reduced antibiotic susceptibility of causative pathogens and
pathophysiological changes associated with critical illness. These
pathophysiological changes, for example altered renal function or
hypoalbuminaemia, can influence antibiotic pharmacokinetics
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(PK) and consequently the achievement of PK/pharmacodynamic
(PD) targets.5,6
Flucloxacillin is a b-lactam antibiotic frequently used in the
treatment of different infections caused by Gram-positive bacteria,
such as penicillinase-producing staphylococci, including MSSA. It is
metabolized to a limited extent and the unchanged drug and
metabolites are excreted in the urine by glomerular filtration and
tubular secretion. Flucloxacillin is approximately 95% bound to
serum proteins and has a half-life of about 1 h.7 The clinical out-
come of b-lactam antibiotics is related to the time the unbound (or
free) drug concentration remains above the MIC of the targeted
pathogen, fT>MIC.
8 In order to devise rational and individualized
dosing regimens of flucloxacillin that ensure sufficient fT>MIC, it is
of importance to understand its PK behaviour and to identify rele-
vant covariates influencing this PK. Because of its high protein bind-
ing and the relationship between unbound drug and outcome, the
unbound PK of flucloxacillin are of special interest. There is, how-
ever, limited knowledge on the PK of flucloxacillin, especially in crit-
ically ill patients.
In view of the above, we performed a population PK study of
total and unbound flucloxacillin in an adult critically ill patient
population. Our objectives were to describe population PK and opti-
mized dosing regimens for flucloxacillin in critically ill patients.
Furthermore, we sought to externally validate the model as well
as quantify the value of various patient-specific covariates explain-
ing altered flucloxacillin PK behaviour.
Patients and methods
Patients and samples
PK data were obtained from 35 patients treated with intermittent flucloxa-
cillin for a (suspected) infection in the 30 bed tertiary referral ICU at the
Royal Brisbane and Women’s Hospital in Brisbane, Australia. This study
comprised data from two different sources. The first dataset was from a
previously published prospective clinical study, performed between May
and December 2009.5 This dataset consisted of 10 patients with hypoalbu-
minaemia (serum albumin concentration 32 g/L). After at least 24 h of
treatment, timed samples were collected at 30, 45, 60, 90, 120, 150 and
180 min (q4h dosing regimens) or 300 min (q6h dosing regimens) after the
30 min infusion. In all samples, both total and unbound flucloxacillin con-
centrations were measured. Data for the other 25 patients originated from
a prospective observational study that was conducted as part of the b-lac-
tam therapeutic drug monitoring (TDM) programme, between May 2012
and July 2014.9 For 19 of these patients, only unbound flucloxacillin con-
centrations were available; for the other 6 patients, both total and unbound
concentrations were available. For the majority of these patients, both mid
and trough levels were obtained in one dosing interval. Samples were
obtained after at least four doses, between Days 1 and 5.
Bioanalytical method
The samples obtained for the prospective study were frozen at #80C and
analysed within 8 months after the sample was drawn, in accordance with
the results of the long-term stability investigation.10 Samples collected
during the TDM programme were centrifuged within 1 h of collection and
analysed directly. All samples were analysed using a validated HPLC-UV
method.
Detailed information on the bioanalytical methods is available as
Supplementary data (Appendices 1–3) at JAC Online.
PK analysis
We developed an integrated PK model for total and unbound flucloxacillin
PK using the non-linear mixed-effects modelling package NONMEM.
Detailed information on methodological model building and validation is
available in the Supplementary data.
External validation
Two external datasets were used for the external validation of the predict-
ive performance of the PK model. The first external dataset, the Brisbane
dataset, consisted of 28 unbound flucloxacillin concentrations from 20 crit-
ically ill patients admitted to the ICU of the Royal Brisbane and Women’s
Hospital. The second external dataset, the Nijmegen dataset, consisted of
34 total and unbound flucloxacillin concentrations from 14 critically ill
patients admitted to the ICU of the Radboud University Medical Center in
Nijmegen, The Netherlands. Detailed information on the external patient
cohorts is available in the Supplementary data.
Total and unbound flucloxacillin plasma concentrations were predicted
by fixing the population PK parameters to the final estimates of the previ-
ously developed model and setting maximum evaluations (MAXEVAL) to 0.
The impact of the identified covariates was validated by means of differen-
ces in predictive performance of the population PK model without covari-
ates (the structural model) and with covariates (the final model). To this
end, the differences in bias (percentage error) and precision (absolute per-
centage error), calculated using Equations 1 and 2, between the structural
and final model were assessed. A P value of 0.05 was used as a cut-off value
for statistical significance. Since the data were not normally distributed, as









where Cpredi and Cobsi represent the ith predicted (PRED, population predic-
tion) and observed concentration, respectively.
Also, visual predictive checks (VPCs) were compared visually and it was
evaluated whether there was bias present in the model itself. Models where
0 was included in the IQR of the median percentage error were considered
unbiased.
Monte Carlo dosing simulations
Using the final population PK model, total and unbound flucloxacillin con-
centration–time profiles were predicted based on Monte Carlo simulations
following two frequently prescribed dosing regimens: 1 g q6h and 2 g q4h.
These dosing regimens were simulated for the first 24 h of treatment of a
typical patient with all median characteristics of the population but with an
estimated glomerular filtration rate (eGFR) of the 10th (33 mL/min) and
90th percentile (153 mL/min) and with a serum albumin concentration of
the 10th (15 g/L) and 90th percentile (30 g/L).
Second, the PTA, being the percentage of patients with an unbound flu-
cloxacillin concentration remaining above a specified MIC during the whole
dosing interval (100%fT>MIC),
8 was calculated for different dosing regimens.
Simulations of four frequently prescribed dosing regimens (1 g q6h, 1 g q4h,
2 g q6h and 2 g q4h) for patients with all median characteristics of the
population but with three different eGFR values (33, 96 and 153 mL/min)
were performed. Each dosing regimen was simulated 1000 times per eGFR
value. Since the MIC distribution of flucloxacillin for Staphylococcus aureus
is lacking but suggested to be similar to that of cloxacillin,12 the target MICs
were based on the MIC distribution of cloxacillin for S. aureus according to
EUCAST. The epidemiological cut-off value (ECOFF) of this pathogen for
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that the majority (55%) of the isolated S. aureus have an MIC of 0.25 mg/
L.13 Additionally, the PTA for the ECOFF of oxacillin as a surrogate for fluclox-
acillin12 for MSSA, 2.0 mg/L,13 was also evaluated.
Statistical analysis
Spearman correlation tests were used to test the correlation between the
protein binding (%) of flucloxacillin, calculated as (1#unbound
fraction)%100, and (i) the total flucloxacillin concentration and (ii) the
serum albumin concentration. The Shapiro–Wilk test was used to assess
whether the data were normally distributed. Wilcoxon matched-pairs tests
were used to assess the differences between the predictive performance of
the structural model and the predictive performance of the final model in
the external datasets. All abovementioned tests were performed using
GraphPad Prism version 8.0.2 for Windows, GraphPad Software, San Diego,
CA, USA, www.graphpad.com.
Ethics
Approval for the prospective study, from which 10 patients for the method
development dataset originated, was obtained by the ethics committee of
the Royal Brisbane and Women’s hospital (protocol HREC/09/QRBW/85)
and written informed consent was obtained for each patient prior to
entering the study. For the other 25 patients included in the model-
building dataset and the 20 patients in the Brisbane external dataset, a
waiver for informed consent was granted by the ethics committee of
the Royal Brisbane and Women’s Hospital, since blood sampling
was performed as part of the local TDM programme. For the Nijmegen
external dataset, the study protocol was evaluated by the local ethics
committee and the need for written informed consent was waived due
to its observational nature.
Results
Patients and samples
Patient characteristics are shown in Table 1. The majority of the
patients were treated with flucloxacillin for bloodstream or re-
spiratory infections, at doses ranging from 1 g q6h to 2 g q2h.
For all patients, flucloxacillin dose was at the discretion of the
treating intensivist. In total, 79 total and 104 unbound flucloxa-
cillin plasma concentrations were collected, obtained at a me-
dian of 30 h after the start of flucloxacillin treatment (range:
0.5–168 h) and a median of 2 h (range: 0.5–6 h) after the most
recent administration. Measured total concentrations ranged
from 1.0 to 202 mg/L and measured unbound concentrations
ranged from 0.1 to 30 mg/L.
Protein binding
The observed protein binding of flucloxacillin (%), calculated per
analysed patient sample as (1#unbound fraction)%100, ranged
from 63.4% to 97.2%, with a median of 89.4%. The relationship be-
tween unbound and total flucloxacillin concentrations is depicted
in Figure 1; it shows non-linear, saturable protein binding that is
concentration dependent. This was confirmed by the association
between the protein binding of flucloxacillin and total flucloxacillin
concentrations, which was not constant (Spearman correlation
r =#0.63, P = <0.0001). In line with this finding, the protein binding
of flucloxacillin was positively associated with serum albumin con-
centrations (Figure 2, Spearman correlation r = 0.52, P = <0.0001).
Table 1. Patient characteristics
Characteristic Model-building patient cohort (n = 35)
External patient cohorts
Brisbane (n = 20) Nijmegen (n = 14)
Female, n (%) 12 (34) 7 (35) 3 (21)
Age (years) 52 (43–67) 55 (41–62) 61 (51–71)
Total body weight (kg) 95 (73–120) 80 (62–115) 83 (74–96)
BMI (kg/m2) 31 (25–35) 26 (20–34) 27 (24–29)
SOFA score 8 (5–13) 6 (3–10) 9 (5–11)
eGFR (mL/min) 96 (26–166) 52 (11–159) 51 (22–177)
RRT, n (%) 4 (11) 3 (15) 3 (21)
Albumin (g/L) 21 (15–34) 21 (15–33) 15 (10–26)
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Figure 1. Unbound versus total flucloxacillin concentrations, measured
in 79 samples from 16 patients.
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Analysed serum albumin concentrations ranged from <15 mg/L to
34 g/L, with a median of 21 g/L.
PK analysis
A two-compartmental model with first-order elimination provided
the best fit for logarithmically transformed data. In line with the
observations in Figure 1, non-linear protein binding resulted in a
better fit than linear protein binding and was described by the fol-
lowing equation:14
Ctotal ¼ Cunbound þ ðBmax  CunboundÞ=ðKd þ CunboundÞ (3)
In Equation 3, Ctotal is the total flucloxacillin concentration, Cunbound
is the unbound flucloxacillin concentration and (Bmax% Cunbound)/
(Kd! Cunbound) represents the bound flucloxacillin concentration,
where Bmax is the maximum binding capacity and Kd is the equilib-
rium dissociation constant.
The multivariate covariate analysis revealed that there was a
statistically significant association between serum albumin con-
centration and Bmax and between eGFR and CL, as described by
Equations 4 and 5.
Bmaxðmmol=LÞ ¼ 0:469 ðAlbumin=20Þ1:51 (4)
CL ðL=hÞ ¼ 55:4 ðeGFR=90Þ0:809 (5)
The associations between the covariates and the PK parameters
are depicted in Figure 3. With these associations in the model,
the between-patient variability (BPV) of Bmax decreased from
42.2% to 30.4% and the BPV of CL decreased from 88.1% to
71.6%.
Parameter estimates of the different model-building steps are
shown in Table 2. Detailed information on the results of methodo-
logical model building and validation, including the VPC (Figure S1),
is available in the Supplementary data (Appendix 2).
External validation
Table 1 shows the characteristics of the patients in the different
datasets. Table 3 shows that, for both external datasets, the pre-
dictive performance of the final model was statistically significant-
ly better than the predictive performance of the structural model,



















Figure 2. Protein binding of flucloxacillin (%), calculated as
(1#unbound fraction)%100, versus serum albumin concentrations,












































Figure 3. Covariate relationship between (a) serum albumin concentrations and Bmax and (b) eGFR and CL of unbound flucloxacillin for the final
model, for all patients for whom both total and unbound concentrations were measured (n = 16). The dots represent the individual estimates of (a)
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percentage errors. For both external datasets, the structural as
well as the final model proved to be unbiased for predicting the un-
bound and total flucloxacillin concentrations. The VPCs (Figures S2
and S3) show that the final model, with covariates, better pre-
dicted the observed concentration–time data of both external
datasets than the model without covariates.
Monte Carlo dosing simulations
Patients with higher eGFRs and lower serum albumin concentra-
tions had lower total flucloxacillin concentrations (Figure 4a and c).
For unbound flucloxacillin, simulations indicated that higher eGFRs
resulted in lower unbound concentrations. Serum albumin concen-
trations did not affect unbound concentrations (Figure 4b and d).
Figure 5 shows the difference in PTA for the frequently
prescribed dosing regimens 1 g q6h, 1 g q4h, 2 g q6h and 2 g q4h,
for different simulated eGFRs and different MICs of the targeted
pathogen. When targeting the ECOFF of cloxacillin for S. aureus,
0.5 mg/L, a dosing regimen of 1 g q6h resulted in a PTA of 91% for
patients with an eGFR of 33 mL/min. A dosing regimen of 2 g q4h
resulted in a PTA of 87% for patients with an eGFR of 96 mL/min
and a PTA of 71% for patients with an eGFR of 153 mL/min.
The PTA for an MIC of 0.25 mg/L, the MIC of the majority of
targeted pathogens,13 was >90% for patients with an eGFR of
96 mL/min treated with a dosing regimen of 2 g q4h. For patients
with a higher eGFR, a PTA of >90% was only reached for pathogens
with an MIC of0.125 mg/L and a dosing regimen of 2 g q4h. The
PTA for an MIC of 2.0 mg/L, the ECOFF of oxacillin for MSSA, and a
dosing regimen of 2 g q4h was 95% for patients with an eGFR of
33 mL/min, 57% for patients with an eGFR of 96 mL/min and 36%
for patients with an eGFR of 153 mL/min.
Discussion
This is, to the best of our knowledge, the first study where both
the PK and the covariates affecting the PK of total and unbound
Table 2. Parameter estimates of the different model-building steps
Parameters
Structural model Final model Bootstrap (n = 1000) of model with covariates
estimate RSE (%) estimate RSE (%) estimate 95% CI
Bmax (mmol/L) 0.46 14.5 0.469 14.1 0.478 0.316–0.622
Kd (mmol/L) 0.0397 15.3 0.0441 16.6 0.0450 0.0260–0.0621
CL (L/h) 54.6 13.6 55.4 11.4 55.2 42.8–68.1
V1 (L) 51.5 11.5 52.7 12.0 53.3 36.9–68.6
V2 (L) 55.9 11.9 56.8 11.8 57.3 41.6–72.0
Q (L/h) 66.4 25.8 67.2 26.0 65.6 32.6–102
BPV
Bmax (%CV) 42.2 23.3 30.4 19.2 28.5 14.4–41.1
CL (%CV) 88.1 11.7 71.6 15.8 68.9 43.7–96.1
Residual variability
proportional error, unbound flucloxacillin 0.222 11.6 0.222 11.2 0.212 0.169–0.275
proportional error, total flucloxacillin 0.161 11.5 0.160 11.6 0.150 0.112–0.203
Covariates
albumin — — 1.51 28.6 1.52 0.521–2.50
eGFR — — 0.809 24.2 0.809 0.365–1.02
CV, coefficient of variation; RSE, relative standard error.
Table 3. Predictive performance of the structural and final model in two external datasets
Brisbane external dataset (n = 20) Nijmegen external dataset (n = 14)
Characteristics structural model final model P structural model final model P
Total flucloxacillin
error (%) NA NA 18.1 (#54.8 to 66.4) #11.0 (#57.1 to 28.3) 0.0005
absolute error (%) NA NA 55.3 (28.5–77.6) 39.6 (19.2–59.6) 0.004
Unbound flucloxacillin
error (%) #59.4 (#83.4 to 14.3) #5.80 (#36.9 to 29.7) 0.01 #49.1 (#86.1 to 9.80) #27.8 (#64.5 to 21.2) 0.04
absolute error (%) 70.3 (40.4–92.0) 33.4 (10.9–58.4) 0.0005 59.2 (32.3–88.9) 51.7 (25.2–74.9) 0.01
Values are expressed as median (IQR). A one-sided Wilcoxon matched-pairs test was used to test differences between the performance of the struc-
tural model and the final model. NA, not available.
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flucloxacillin in critically ill patients are described with the aim of
optimizing flucloxacillin dosing regimens. In a previous study per-
formed at the Royal Brisbane and Women’s Hospital,5 in which 10
of the patients from this current study were included, patients with
hypoalbuminaemia (serum albumin concentration 32 g/L) and
without severe renal dysfunction (serum creatinine <170 lmol/L)
were recruited to develop a PK model. Only unbound flucloxacillin
concentrations were used for that PK model and thus no protein-
binding model was applied. As expected, our PK parameter esti-
mates for central volume of distribution (V1), peripheral volume
of distribution (V2) and intercompartmental clearance (Q) were
similar to those reported in the previously performed study. The
PK parameter estimate for CL was lower in the current study,
which can be explained by the fact that patients with severe renal
dysfunction were excluded from the previously published study,
but not from the current study. In a recently published report
describing the total and unbound PK of flucloxacillin in non-
critically ill patients, a two-compartment model with non-linear
protein binding was also found to best describe the data, with a
parameter estimate for Bmax in the same range.
15
We showed that a lower eGFR was related to a lower flucloxa-
cillin CL; BPV of flucloxacillin CL decreased from 88.1% to 71.6%
upon inclusion of eGFR. The large remaining BPV can be explained
by: (i) flucloxacillin is not only eliminated by glomerular filtration,
but also via tubular secretion and non-renal mechanisms, where
non-renal mechanisms account for approximately 30% of total
CL;7,16,17 and (ii) eGFR calculated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation is not validated in
critically ill patients and it is known that serum creatinine has
demerits in this population, considering the rapid (patho)physio-
logical changes in these patients.18 However, our results show that
eGFR was related to unbound flucloxacillin CL, and thus flucloxacil-
lin exposure and PTA, and this is an easily accessible parameter.
Furthermore, augmented CLCR (>130 mL/min/1.73 m
2) is present
in approximately 50% of patients admitted to the ICU.19
Therefore, we believe this parameter is of value when optimizing
dosing regimens for the individual critically ill patient.
We demonstrated that, due to non-linear protein binding
across the observed concentration range, total flucloxacillin con-
centrations are not representative of unbound concentrations.
This is in line with the finding of a previous study, where significant
differences between predicted (from total concentrations) and
measured unbound concentrations for flucloxacillin were
reported.20 Most assays used in TDM programmes and PK studies
of critically ill patients measure total b-lactam antibiotic concen-
trations.21,22 In order to individualize dosing regimens, published
plasma protein-binding percentages derived from studies per-
formed in non-critically ill patients are used to calculate unbound
250
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Figure 4. Illustration of the effect of the covariates eGFR (mL/min) and serum albumin concentration (g/L) on the concentration–time curve of flu-
cloxacillin as assessed by Monte Carlo simulations of the first 24 h of treatment of a virtual critically ill patient, with all median characteristics of the
population, but with two different eGFR values and two different serum albumin concentrations. Both total and unbound flucloxacillin concentrations
were simulated for two different IV dosing regimens: (a) total flucloxacillin concentrations after 1 g q6h; (b) unbound flucloxacillin concentrations
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concentrations from the measured total concentrations.20,23 Our
results show that these assays may not be suitable in clinical prac-
tice, where the target is defined as the unbound concentration, i.e.
fT>MIC. An explanation for the non-linear association between un-
bound and total concentrations is that when the concentration of
flucloxacillin in plasma increases, binding sites on proteins are in-
creasingly saturated, resulting in a higher fraction of unbound drug
in plasma, i.e. saturable protein binding.24 In our data, differences
in the unbound fraction of flucloxacillin could be partly explained
by differences in serum albumin concentrations; serum albumin
concentrations were associated with Bmax. A lower serum albumin
concentration was related to lower protein binding (and a higher
unbound fraction) and resulted in a lower exposure of total fluclox-
acillin, but not unbound flucloxacillin. This finding is similar to what
was observed in non-critically ill patients.15 Consequently, patients
with low serum albumin concentrations are most likely to have
lower flucloxacillin protein binding than the values observed in the
literature. This is of special importance in the ICU, where 40%–50%
of the patients have low serum albumin concentrations (<25 g/
L).25 In clinical practice, this means that when only total flucloxa-
cillin concentrations are measured and converted into unbound
concentrations using protein-binding values observed in the litera-
ture, i.e. 95%,7 in order to evaluate the attainment of the PK/PD
target of 100%fT>MIC, there is a risk of underestimating unbound
concentrations. As a consequence, unnecessarily high flucloxacillin
doses may be selected when dosing regimens are based on meas-
ured total concentrations.
We validated the impact of eGFR and serum albumin concen-
trations on the flucloxacillin PK in two external datasets from two
different countries. Since there is no defined therapeutic window
for flucloxacillin and TDM is not routinely applied, we chose to com-
pare the population-predicted concentrations (PRED) from the
model with and without the covariates. There are no standardized
requirements for bias and precision when applying a PK model to
an external dataset, therefore we used a statistically significant
endpoint to evaluate the predictive performance. For both data-
sets, we found a significant improvement in predictive perform-
ance when the covariates were added to the model. This confirms
that the identified covariates, serum albumin concentration and
eGFR, are of relevance for flucloxacillin exposure in critically ill
patients.
Our results show that large differences in PTA are encountered
for different eGFRs and target MICs, indicating that it is of import-
ance to combine information on the targeted pathogen (MIC) with
information on the patient (e.g. renal function) to devise a rational
dosing regimen. In general, when aiming for an effectiveness tar-
get of 100%fT>MIC,
8 a dosing regimen of 2 g q4h is adequate for
patients with an eGFR of <96 mL/min and where no MIC of the tar-
geted pathogen is available. For patients with an eGFR of33 mL/
min, a dosing regimen of 1 g q6h should be adequate. For patients
with an eGFR of96 mL/min and who are infected with moderate-
ly susceptible pathogens, TDM using unbound flucloxacillin con-
centrations is advised to devise an optimal dosing regimen. For
patients infected with MSSA, currently used intermittent dosing
regimens are unlikely to result in an acceptable PTA, particularly in
patients without renal impairment. For these patients, measure-
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Figure 5. Monte Carlo simulations (n = 1000) and PTA for achieving 100%fT>MIC at t = 24 h for various eGFRs calculated by the CKD-EPI equation, for
four different IV flucloxacillin dosing regimens administered to critically ill patients: (a) 1 g q6h; (b) 1 g q4h; (c) 2 g q6h; and (d) 2 g q4h. The ECOFF of
cloxacillin (as a surrogate for flucloxacillin) for S. aureus is 0.5 mg/L, according to EUCAST.14
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Our study has several limitations. First, the limited number of
patients and total and unbound flucloxacillin concentrations that
were used for model building has likely resulted in a limited power
to identify covariates that have a significant impact. This might, for
example, explain why no statistically significant relationship was
found between renal replacement therapy (RRT) (n = 4 patients)
and flucloxacillin. However, we believe that with this dataset we
were able to identify the most clinically relevant covariates, which
was also confirmed in two external patient cohorts. Also, although
our dataset consisted of a limited number of patients, it is the
largest ICU patient dataset used for population PK modelling of
flucloxacillin to date. Second, our PK model is solely based on
patients receiving intermittent, and not continuous, infusion of
flucloxacillin. This is due to the nature of this retrospective co-
hort in a centre where intermittent infusion is current standard
practice in the ICU. Third, all patients in the model development
and both external datasets had a serum albumin concentration
below 35 g/L. Therefore, extrapolation of this model to patients
with higher serum albumin concentrations should be per-
formed with caution.
Nevertheless, our data represent an important step forward,
as this study is the first to develop and validate a PK model
incorporating both total and unbound flucloxacillin. This
resulted in several relevant findings that are easily applicable to
the optimization of flucloxacillin dosing regimens in daily clinic-
al practice.
Conclusions
We showed that both eGFR and serum albumin concentration
have a significant impact on flucloxacillin exposure and PK/PD tar-
get attainment and should be taken into account when devising a
rational dosing regimen for critically ill patients. For patients with
high CLCR and infected with moderately susceptible pathogens,
TDM is advised, as a risk of underexposure exists. Dose adjust-
ments should be based on unbound concentrations, due to the
non-linear protein binding of flucloxacillin and the high prevalence
of hypoalbuminaemia in this patient population.
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